Reported resultsCompany-reported
What was reported
Cambridge, Mass., May 7, 2026 – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported first quarter 2026 financial results and provided updates across the company’s hematology and genetic disease franchises.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 7, 2026 · Open the source ↗
What the evidence supports
Beam Therapeutics published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineBeam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business UpdatesU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 7, 2026 · Open the source ↗
Press release lead paragraphCambridge, Mass., May 7, 2026 – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported first quarter 2026 financial results and provided updates across the company’s hematology and genetic disease franchises.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 7, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:51 UTC
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.